Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›TRDA›ENTR-601-44 · ELEVATE-44

ENTR-601-44 · ELEVATE-44

Ensayo de Entrada Therapeutics, Inc. en Distrofia muscular de Duchenne.

Más ensayos de: Distrofia muscular de Duchenne.

Todo sobre el fármaco: ENTR-601-44.

Fase
Fase 1/2
Estado
Reclutando pacientes
Participantes
24
previstos
Centros
14
Fin del objetivo primario
mar 2029
estimado por el promotor

Título oficial en el registro (en inglés): A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jun 2025.

De principio a fin

  1. Empieza el ensayo (jun 2025)
  2. Hoy
  3. Lectura de resultados mar 2029 (prevista)

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period) (From baseline through End of Study (up to 62 weeks).) (del registro, en inglés)

Qué se prueba

Es un estudio del medicamento en investigación ENTR-601-44 en participantes con distrofia muscular de Duchenne.

Lo que dice el documentoThis is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-44 is, learn about any side effects, and look at the potential positive effects of ENTR-601-44, compared to placebo.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-44 is, learn about any side effects, and look at the potential positive effects of ENTR-601-44, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-44 and placebo are both called study treatments. The study has 2 parts: * Part A * A Double-Blind Period, to evaluate if ENTR-601-44 is safe and to determine the best dose of ENTR-601-44 for Part B. * Following the Double-Blind period, participants will roll into an open-label treatment period during which the safety and efficacy of extended dosing will be evaluated. * Part B * To further evaluate the effect and safety of ENTR-601-44 at the dose determined in Part A. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injection) into a vein over the course of several weeks in Part A and in Part B * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and exercise tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a result of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

Más ensayos de TRDA

EnsayoFaseEstadoLectura de resultados
ENTR-601-45 · ELEVATE-45Fase 1/2Reclutando pacientesmar 2029 (prevista)
ENTR-601-44 · ELEVATE-LTEFase 2Aún sin reclutarmar 2032 (prevista)
Natural History Study of MNGIEno aplicaSuspendidofeb 2025 (prevista, ya pasada: sin actualizar en el registro)

Todos los de TRDA, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07037862), actualizada en ago 2026.